Background: Germline genetic polymorphisms in certain genes are associated with the response to anthracycline-and taxane-based neoadjuvant chemotherapy in breast cancer (BC). This translational study aims to evaluate the potential role of rs1042713 in the beta 2-adrenergic receptor (ADRB2) gene in predicting pathological complete responses (pCRs) to taxane-and platinum-based neoadjuvant chemotherapy in locally advanced breast cancer (LABC).
Introduction
Neoadjuvant chemotherapy is a widely accepted treatment modality in women with newly diagnosed early breast cancer (BC), especially in locally advanced breast cancer (LABC). 1, 2 Neoadjuvant chemotherapy helps reduce tumor volume, thus enabling more patients to receive breast-conserving surgery. In addition, it offers the opportunity to assess tumor response in the resection specimen. 
202
Du et al that pCR after neoadjuvant chemotherapy is associated with better long-term survival. [4] [5] [6] Among women who receive neoadjuvant chemotherapy, the clinical response rate is up to 70%, but only ~15%-30% of patients achieve pCR. 1, 2, 7 Novel predictive biomarkers that can predict tumor response prior to the initiation of chemotherapy are valuable in making individualized treatment decisions and maximizing efficacy in cancer patients. Germline genetic polymorphisms include minor changes in DNA sequences that can modify the structure, expression or activity of the proteins encoded by genes. 8 Previous research has demonstrated that germline genetic polymorphisms located in WT1, IGF1R, MDM2 and CD24 genes are associated with a response to anthracycline-and taxane-based neoadjuvant chemotherapy in BC. 3, [9] [10] [11] ADRB2 is localized to the 5q32 chromosomal region. The encoded protein, the beta 2-adrenergic receptor, is a member of the G protein-coupled receptor superfamily. 12 The association between polymorphisms in the ADRB2 genes and the risk of several diseases has been previously studied. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity, and type 2 diabetes. [12] [13] [14] [15] Huang et al demonstrated that the presence of the 27Glu (rs1042714) mutation in ADRB2 or the 64Arg mutation in ADRB3 (rs4994) was associated with a decreased risk for BC, especially when both mutations were present. 16 rs1042713 is an A/G single-nucleotide variation at nucleotide position 46 in the ADRB2 gene (AGA to GGA). The mutation substitutes the 16th amino acid of the translated protein chain from arginine to glycine. It is still unclear whether this polymorphism in the ADRB2 gene has a predictive role in response to neoadjuvant chemotherapy in LABC.
ADRB2 is one of the target genes of the microRNA (miRNA) let-7 family. 17 It has been reported that resistance to paclitaxel and cisplatin is partly mediated by miRNA let-7. 18 We hypothesized that rs1042713 in the ADRB2 gene could predict response to taxane-and platinum-based neoadjuvant chemotherapy in BC. In this translational study, we identified the single-nucleotide polymorphism (SNP) in the rs1042713 mutation from participants of two prospective studies in which patients received weekly paclitaxel and cisplatin as neoadjuvant chemotherapy.
Materials and methods study populations
From October 2013 until November 2016, 130 patients with LABC were recruited for this study. The inclusion criteria were females between the ages of 18 and 70 years with histologically confirmed but untreated large operable BC (T size ≥2 cm and N0-2). Patients who suffered from other malignancies were excluded. Other inclusion and exclusion criteria have been described elsewhere. 19 Patients enrolled in this study were participants from two open-label, prospective trials (SHPD001 and SHPD002). All participants from the two trials who were willing to take part in this study and provide informed consent were enrolled in this study. SHPD001 (NCT02199418) was a Phase II study evaluating weekly treatment with paclitaxel in combination with cisplatin as neoadjuvant therapy for LABC patients. SHPD002 (NCT0222199) is a prospective, randomized, open-label study comparing preoperative weekly treatment with paclitaxel and cisplatin with or without endocrine therapy in patients with operable hormone receptor-positive and triple-negative LABC. In these two trials, patients were scheduled to receive intravenous weekly infusions of 80 mg/m 2 
Results

associations of genotype with clinicopathologic parameters
The genotypic distribution for rs1042713 was tested for deviation from HWE and showed no deviation (data not shown). There was a correlation between the rs1042713 genotypes and the clinicopathologic parameters of primary BC. 
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Du et al (Table 3 ). Further analysis showed that there were significant differences in rs1042713 between the pCR and non-pCR patients in luminal type (P=0.035) and HER2-positive breast cancers (P=0.045) (Figure 1 ).
Discussion
In this translational study, we report for the first time that ADRB2 rs1042713 could predict pCR to taxane-and platinum-based neoadjuvant chemotherapy in LABC, especially in luminal type and HER2-positive breast cancers. In the neoadjuvant setting, it is important to identify nonresponders to avoid ineffective treatments and provide alternative therapies such as surgery or switching to a noncross resistant chemotherapy regimen.
In this study, we showed that the ADRB2 rs1042713 genotypes were associated with ER status. Recent studies have found that similarities and interactions exist between the signaling pathways of ERs (ERα, ERβ, GPR30) and β adrenoceptors (β1, β2 and β3 adrenoceptors). 21 GPR30, a recently discovered receptor, shares structural features with the β adrenoceptors. GPR30 has sites for protein kinase A phosphorylation, PDZ binding motifs, and interacts with A-kinase anchoring protein 5 (AKAP5), all of which enable its interaction with the β adrenoceptors pathways. 21 Our previous study investigated the association between β2 adrenoceptor (encoded by the ADRB2 gene) and clinical outcomes in BC; we found that in hormone receptor-positive BC patients, strong β2 adrenoceptor expression was correlated with better disease-free survival than weak β2 adrenoceptor expression. 22 These findings were consistent, indicating that there are interactions between ERs and β adrenoceptors that help coordinate one another.
Some studies have demonstrated that germline polymorphisms have an effect on patient response to therapy for malignant diseases. [23] [24] [25] However, the association between polymorphisms in the ADRB2 gene and response to neoadjuvant chemotherapy in BC has not yet been reported. Our data showed that ADRB2 rs1042713 can predict pCR to taxane-and platinum-based neoadjuvant chemotherapy in BC. Wu et al used modified miRNA probes to detect let-7a via in situ hybridization in formalin-fixed and paraffin-embedded sections from BC patients who received epirubicin-based neoadjuvant chemotherapy; they found that lower let-7a expression was associated with epirubicin resistance in BC tumors. 26 They also showed that let-7a upregulation in an epirubicin-resistant SK-3rd sphere cell line sensitized this cell line to epirubicin and upregulated let-7a expression, increasing the apoptotic cell population in the SK-3rd sphere cells compared to the negative control groups. 26 Additionally, Wang et al found that the ADRB2 gene was a target of let-7f. 17 Under static conditions, let-7f actively repressed translation and established basal levels of β 2 adrenoceptor expression. During agonist activation of β 2 adrenoceptor, let-7f levels decreased, resulting in depressed ADRB2 gene silencing and a subsequent attenuation of agonist-promoted downregulation of β 2 adrenoceptor. 17 As a downstream molecule of let-7, ADRB2 may be involved in the regulation of miRNAs in let-7-related gene networks. Finally, changes in the function of ADRB2 itself may also influence the regulation of the let-7 response to chemotherapy. The correlation between response to chemotherapy and miRNA in let-7-related gene networks will be further investigated in our future work.
We acknowledge that the present study has some limitations. The sample size of the patient cohort was small. Our findings indicate that the SNP ADRB2 rs1042713 was associated with response to neoadjuvant chemotherapy and may have a potential role as a predictive marker in clinical settings. However, we acknowledge that we did not investigate other SNPs located in the ADRB2 gene or miRNAs in the let-7-related gene networks.
Conclusion
The results of the present study showed that ADRB2 rs1042713 can predict pCR to taxane-and platinum-based neoadjuvant chemotherapy in LABC. A significant association was detected between the rs1042713 genotypes and ER status. Further work is needed to clarify the molecular mechanisms underlying this relationship.
